Controlled Substances: 2014 Proposed Aggregate Production Quota for Four Temporarily Controlled Synthetic Cannabinoids, 13076-13077 [2014-05024]
Download as PDF
mstockstill on DSK4VPTVN1PROD with NOTICES
13076
Federal Register / Vol. 79, No. 45 / Friday, March 7, 2014 / Notices
remedial orders are used in the United
States;
(ii) identify any public health, safety,
or welfare concerns in the United States
relating to the requested remedial
orders;
(iii) identify like or directly
competitive articles that complainant,
its licensees, or third parties make in the
United States which could replace the
subject articles if they were to be
excluded;
(iv) indicate whether complainant,
complainant’s licensees, and/or third
party suppliers have the capacity to
replace the volume of articles
potentially subject to the requested
exclusion order and/or a cease and
desist order within a commercially
reasonable time; and
(v) explain how the requested
remedial orders would impact United
States consumers.
Written submissions must be filed no
later than by close of business, eight
calendar days after the date of
publication of this notice in the Federal
Register. There will be further
opportunities for comment on the
public interest after the issuance of any
final initial determination in this
investigation.
Persons filing written submissions
must file the original document
electronically on or before the deadlines
stated above and submit 8 true paper
copies to the Office of the Secretary by
noon the next day pursuant to section
210.4(f) of the Commission’s Rules of
Practice and Procedure (19 CFR
210.4(f)). Submissions should refer to
the docket number (‘‘Docket No. 3003’’)
in a prominent place on the cover page
and/or the first page. (See Handbook for
Electronic Filing Procedures, Electronic
Filing Procedures 4). Persons with
questions regarding filing should
contact the Secretary (202–205–2000).
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment. All such requests should be
directed to the Secretary to the
Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All nonconfidential
written submissions will be available for
public inspection at the Office of the
Secretary and on EDIS.5
4 Handbook for Electronic Filing Procedures:
https://www.usitc.gov/secretary/fed_reg_notices/
rules/handbook_on_electronic_filing.pdf
5 Electronic Document Information System
(EDIS): https://edis.usitc.gov.
VerDate Mar<15>2010
18:39 Mar 06, 2014
Jkt 232001
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and of sections 201.10 and 210.8(c) of
the Commission’s Rules of Practice and
Procedure (19 CFR 201.10, 210.8(c)).
By order of the Commission.
Issued: February 28, 2014.
William R. Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2014–04945 Filed 3–6–14; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA #390P]
Controlled Substances: 2014 Proposed
Aggregate Production Quota for Four
Temporarily Controlled Synthetic
Cannabinoids
Drug Enforcement
Administration (DEA), Department of
Justice.
ACTION: Notice of a proposed 2014
aggregate production quota for four
synthetic cannabinoids.
AGENCY:
Four synthetic cannabinoids:
quinolin-8-yl 1-pentyl-1H-indole-3carboxylate (PB-22; QUPIC); quinolin-8yl 1-(5-fluoropentyl)-1H-indole-3carboxylate (5-fluoro-PB-22; 5F-PB-22);
N-(1-amino-3-methyl-1-oxobutan-2-yl)1-(4-fluorobenzyl)-1H-indazole-3carboxamide (AB-FUBINACA); and N(1-amino-3,3-dimethyl-1-oxobutan-2-yl)1-pentyl-1H-indazole-3-carboxamide
(ADB-PINACA) were temporarily placed
in schedule I of the Controlled
Substances Act (CSA) by a final order
published by the DEA on February 10,
2014 (79 FR 7577). This means that any
manufacturer that wishes to
manufacture PB-22, 5F-PB-22, ABFUBINACA, or ADB-PINACA after
February 10, 2014, must be registered
with the DEA and have obtained a
manufacturing quota for PB-22, 5F-PB22, AB-FUBINACA, or ADB-PINACA
pursuant to 21 CFR part 1303.
The DEA cannot issue individual
manufacturing quotas for PB–22, 5F–
PB–22, AB–FUBINACA, or ADB–
PINACA unless and until it establishes
an aggregate production quota.
Therefore, this notice proposes a 2014
aggregate production quota for PB–22,
5F–PB–22, AB–FUBINACA, and ADB–
PINACA.
DATES: Comments or objections should
be received on or before April 7, 2014.
ADDRESSES: To ensure proper handling
of comments, please reference ‘‘Docket
SUMMARY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
No. DEA–390P’’ on all electronic and
written correspondence. The DEA
encourages that all comments be
submitted electronically through
www.regulations.gov using the
electronic comment form provided on
that site. An electronic copy of this
document is also available at
www.regulations.gov for easy reference.
Paper comments that duplicate the
electronic submission are not necessary
as all comments submitted to
www.regulations.gov will be posted for
public review and are part of the official
docket record. Written comments
submitted via regular or express mail
should be sent to the Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152.
FOR FURTHER INFORMATION CONTACT:
Ruth A. Carter, Office of Diversion
Control, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152, Telephone: (202) 598–6812.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
The Freedom of Information Act
applies to all comments received. All
comments received are considered part
of the public record and made available
for public inspection online at
www.regulations.gov and in the DEA’s
public docket. Such information
includes personal identifying
information (such as your name,
address, etc.) voluntarily submitted by
the commenter.
If you want to submit personal
identifying information (such as your
name, address, etc.) as part of your
comment, but do not want it to be
posted online or made available in the
public docket, you must include the
phrase ‘‘PERSONAL IDENTIFYING
INFORMATION’’ in the first paragraph
of your comment. You must also place
all the personal identifying information
you do not want posted online or made
available in the public docket in the first
paragraph of your comment and identify
what information you want redacted.
If you want to submit confidential
business information as part of your
comment, but do not want it to be
posted online or made available in the
public docket, you must include the
phrase ‘‘CONFIDENTIAL BUSINESS
INFORMATION’’ in the first paragraph
of your comment. You must also
prominently identify confidential
business information to be redacted
within the comment. If a comment has
so much confidential business
information that it cannot be effectively
E:\FR\FM\07MRN1.SGM
07MRN1
Federal Register / Vol. 79, No. 45 / Friday, March 7, 2014 / Notices
redacted, all or part of that comment
may not be posted online or made
available in the public docket.
Personal identifying information and
confidential business information
identified and located as set forth above
will be redacted, and the comment, in
redacted form, will be posted online and
placed in the DEA’s public docket file.
If you wish to inspect the DEA’s
public docket file in person by
appointment, please see the FOR
FURTHER INFORMATION CONTACT
mstockstill on DSK4VPTVN1PROD with NOTICES
paragraph.
Background
Section 306 of the CSA (21 U.S.C.
826) requires that the Attorney General
establish aggregate production quotas
for each basic class of controlled
substance listed in schedules I and II
each year. This responsibility has been
delegated to the Administrator of the
DEA by 28 CFR 0.100. The
Administrator, in turn, has redelegated
this function to the Deputy
Administrator, pursuant to 28 CFR
0.104.
The DEA established the 2014
aggregate production quotas for
substances in schedules I and II on
September 9, 2013 (78 FR 55099).
Subsequently, on January 10, 2014, the
DEA published in the Federal Register
a notice of intent to temporarily place
four synthetic cannabinoids: quinolin-8yl 1-pentyl-1H-indole-3-carboxylate (PB22; QUPIC); quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-carboxylate
(5-fluoro-PB-22; 5F-PB-22); N-(1-amino3-methyl-1-oxobutan-2-yl)-1-(4fluorobenzyl)-1H-indazole-3carboxamide (AB-FUBINACA); and N(1-amino-3,3-dimethyl-1-oxobutan-2-yl)1-pentyl-1H-indazole-3-carboxamide
(ADB-PINACA) in schedule I of the CSA
(79 FR 1776). On February 10, 2014, the
DEA published in the Federal Register
a final order to temporarily place these
four synthetic cannabinoids in schedule
I of the CSA (79 FR 7577), making all
regulations pertaining to schedule I
controlled substances applicable to the
manufacture of these four synthetic
cannabinoids, including the
establishment of an aggregate
production quota pursuant to 21 CFR
1303.11.
PB-22, 5F-PB-22, AB-FUBINACA, and
ADB-PINACA were non-controlled
substances when the aggregate
production quotas for schedule I and II
substances were established, therefore,
no aggregate production quotas for PB22, 5F-PB-22, AB-FUBINACA, and ADBPINACA were established at that time.
In determining the 2014 aggregate
production quotas of these four
cannabinoids, the Deputy Administrator
VerDate Mar<15>2010
18:39 Mar 06, 2014
Jkt 232001
considered the following factors in
accordance with 21 U.S.C. 826(a) and 21
CFR 1303.11: (1) Total estimated net
disposal of each substance by all
manufacturers; (2) estimated trends in
the national rate of net disposal; (3) total
estimated inventories of the basic class
and of all substances manufactured from
the class; (4) projected demand for each
class as indicated by procurement
quotas requested pursuant to 21 CFR
1303.12; and (5) other factors affecting
medical, scientific, research, and
industrial needs of the United States
and lawful export requirements, as the
Deputy Administrator finds relevant.
These quotas do not include imports of
controlled substances for use in
industrial processes.
The Deputy Administrator, therefore,
proposes that the year 2014 aggregate
production quotas for the following
temporarily controlled schedule I
controlled substances, expressed in
grams of anhydrous acid or base, be
established as follows:
13077
Dated: February 28, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014–05024 Filed 3–6–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (BJA) Docket No. 1648]
Meeting of the Department of Justice’s
(DOJ’s) National Motor Vehicle Title
Information System (NMVTIS) Federal
Advisory Committee
Office of Justice Programs
(OJP), Justice.
ACTION: Notice of meeting.
AGENCY:
This is an announcement of a
webinar meeting of DOJ’s National
Motor Vehicle Title Information System
(NMVTIS) Federal Advisory Committee
to discuss various issues relating to the
operation and implementation of
NMVTIS.
SUMMARY:
The meeting will take place on
Wednesday March 26, 2014, from 1:00
p.m. to 3:00 p.m. ET.
ADDRESSES: This will be a webinar
N-(1-amino-3,3-dimethyl-1meeting. Those wishing to participate
oxobutan-2-yl)-1-pentylare asked to email their request to the
1H-indazole-3Designated Federal Employee (DFE)
carboxamide (ADB–
PINACA) ............................
15 g listed below.
N-(1-amino-3-methyl-1FOR FURTHER INFORMATION CONTACT:
oxobutan-2-yl)-1-(4Todd Brighton, Designated Federal
fluorobenzyl)-1H-indazoleEmployee (DFE), Bureau of Justice
3-carboxamide (AB–
FUBINACA) .......................
15 g Assistance, Office of Justice Programs,
810 7th Street NW., Washington, DC
quinolin-8-yl 1-(520531; Phone: (202) 616–3879 [note:
fluoropentyl)-1H-indole-3carboxylate (5-fluoro-PB–
this is not a toll-free number]; Email:
22; 5F–PB–22) ..................
15 g Todd.Brighton@usdoj.gov
quinolin-8-yl 1-pentyl-1HSUPPLEMENTARY INFORMATION: This
indole-3-carboxylate (PB–
22; QUPIC) .......................
15 g meeting is open to the public. Members
of the public who wish to participate in
the webinar must register with Mr.
Comments
Brighton at the above address at least
Pursuant to 21 CFR 1303.11, any
seven (7) days in advance of the
interested person may submit written
meeting. Registrations will be accepted
comments on or objections to these
on a space available basis. Access to the
proposed determinations. Based on
meeting will not be allowed without
comments received in response to this
registration. Interested persons whose
notice, the Deputy Administrator may
registrations have been accepted may be
hold a public hearing on one or more
permitted to participate in the
issues raised. In the event the Deputy
discussions at the discretion of the
Administrator decides in his sole
meeting chairman and with approval of
discretion to hold such a hearing, the
the DFE.
Deputy Administrator will publish a
Anyone requiring special
notice of any such hearing in the
accommodations should notify Mr.
Federal Register. After consideration of Brighton at least seven (7) days in
any comments and after a hearing, if one advance of the meeting.
is held, the Deputy Administrator will
Purpose
publish in the Federal Register a final
order establishing the 2014 aggregate
The NMVTIS Federal Advisory
production quota for PB–22, 5F–PB–22, Committee will provide input and
AB–FUBINACA, and ADB–PINACA.
recommendations to the Office of Justice
PO 00000
DATES:
Basic class—Schedule I
Frm 00043
Fmt 4703
Sfmt 4703
Proposed
2014 quota
E:\FR\FM\07MRN1.SGM
07MRN1
Agencies
[Federal Register Volume 79, Number 45 (Friday, March 7, 2014)]
[Notices]
[Pages 13076-13077]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-05024]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA 390P]
Controlled Substances: 2014 Proposed Aggregate Production Quota
for Four Temporarily Controlled Synthetic Cannabinoids
AGENCY: Drug Enforcement Administration (DEA), Department of Justice.
ACTION: Notice of a proposed 2014 aggregate production quota for four
synthetic cannabinoids.
-----------------------------------------------------------------------
SUMMARY: Four synthetic cannabinoids: quinolin-8-yl 1-pentyl-1H-indole-
3-carboxylate (PB-22; QUPIC); quinolin-8-yl 1-(5-fluoropentyl)-1H-
indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22); N-(1-amino-3-methyl-1-
oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-
FUBINACA); and N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
indazole-3-carboxamide (ADB-PINACA) were temporarily placed in schedule
I of the Controlled Substances Act (CSA) by a final order published by
the DEA on February 10, 2014 (79 FR 7577). This means that any
manufacturer that wishes to manufacture PB-22, 5F-PB-22, AB-FUBINACA,
or ADB-PINACA after February 10, 2014, must be registered with the DEA
and have obtained a manufacturing quota for PB-22, 5F-PB-22, AB-
FUBINACA, or ADB-PINACA pursuant to 21 CFR part 1303.
The DEA cannot issue individual manufacturing quotas for PB-22, 5F-
PB-22, AB-FUBINACA, or ADB-PINACA unless and until it establishes an
aggregate production quota. Therefore, this notice proposes a 2014
aggregate production quota for PB-22, 5F-PB-22, AB-FUBINACA, and ADB-
PINACA.
DATES: Comments or objections should be received on or before April 7,
2014.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-390P'' on all electronic and written correspondence.
The DEA encourages that all comments be submitted electronically
through www.regulations.gov using the electronic comment form provided
on that site. An electronic copy of this document is also available at
www.regulations.gov for easy reference. Paper comments that duplicate
the electronic submission are not necessary as all comments submitted
to www.regulations.gov will be posted for public review and are part of
the official docket record. Written comments submitted via regular or
express mail should be sent to the Drug Enforcement Administration,
Attention: DEA Federal Register Representative/ODW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT: Ruth A. Carter, Office of Diversion
Control, Drug Enforcement Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia 22152, Telephone: (202) 598-
6812.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
The Freedom of Information Act applies to all comments received.
All comments received are considered part of the public record and made
available for public inspection online at www.regulations.gov and in
the DEA's public docket. Such information includes personal identifying
information (such as your name, address, etc.) voluntarily submitted by
the commenter.
If you want to submit personal identifying information (such as
your name, address, etc.) as part of your comment, but do not want it
to be posted online or made available in the public docket, you must
include the phrase ``PERSONAL IDENTIFYING INFORMATION'' in the first
paragraph of your comment. You must also place all the personal
identifying information you do not want posted online or made available
in the public docket in the first paragraph of your comment and
identify what information you want redacted.
If you want to submit confidential business information as part of
your comment, but do not want it to be posted online or made available
in the public docket, you must include the phrase ``CONFIDENTIAL
BUSINESS INFORMATION'' in the first paragraph of your comment. You must
also prominently identify confidential business information to be
redacted within the comment. If a comment has so much confidential
business information that it cannot be effectively
[[Page 13077]]
redacted, all or part of that comment may not be posted online or made
available in the public docket.
Personal identifying information and confidential business
information identified and located as set forth above will be redacted,
and the comment, in redacted form, will be posted online and placed in
the DEA's public docket file.
If you wish to inspect the DEA's public docket file in person by
appointment, please see the For Further Information Contact paragraph.
Background
Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney
General establish aggregate production quotas for each basic class of
controlled substance listed in schedules I and II each year. This
responsibility has been delegated to the Administrator of the DEA by 28
CFR 0.100. The Administrator, in turn, has redelegated this function to
the Deputy Administrator, pursuant to 28 CFR 0.104.
The DEA established the 2014 aggregate production quotas for
substances in schedules I and II on September 9, 2013 (78 FR 55099).
Subsequently, on January 10, 2014, the DEA published in the Federal
Register a notice of intent to temporarily place four synthetic
cannabinoids: quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22;
QUPIC); quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-
fluoro-PB-22; 5F-PB-22); N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA); and N-(1-amino-
3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-
PINACA) in schedule I of the CSA (79 FR 1776). On February 10, 2014,
the DEA published in the Federal Register a final order to temporarily
place these four synthetic cannabinoids in schedule I of the CSA (79 FR
7577), making all regulations pertaining to schedule I controlled
substances applicable to the manufacture of these four synthetic
cannabinoids, including the establishment of an aggregate production
quota pursuant to 21 CFR 1303.11.
PB-22, 5F-PB-22, AB-FUBINACA, and ADB-PINACA were non-controlled
substances when the aggregate production quotas for schedule I and II
substances were established, therefore, no aggregate production quotas
for PB-22, 5F-PB-22, AB-FUBINACA, and ADB-PINACA were established at
that time.
In determining the 2014 aggregate production quotas of these four
cannabinoids, the Deputy Administrator considered the following factors
in accordance with 21 U.S.C. 826(a) and 21 CFR 1303.11: (1) Total
estimated net disposal of each substance by all manufacturers; (2)
estimated trends in the national rate of net disposal; (3) total
estimated inventories of the basic class and of all substances
manufactured from the class; (4) projected demand for each class as
indicated by procurement quotas requested pursuant to 21 CFR 1303.12;
and (5) other factors affecting medical, scientific, research, and
industrial needs of the United States and lawful export requirements,
as the Deputy Administrator finds relevant. These quotas do not include
imports of controlled substances for use in industrial processes.
The Deputy Administrator, therefore, proposes that the year 2014
aggregate production quotas for the following temporarily controlled
schedule I controlled substances, expressed in grams of anhydrous acid
or base, be established as follows:
------------------------------------------------------------------------
Proposed 2014
Basic class--Schedule I quota
------------------------------------------------------------------------
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H- 15 g
indazole-3-carboxamide (ADB-PINACA)....................
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)- 15 g
1H-indazole-3-carboxamide (AB-FUBINACA)................
quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate 15 g
(5-fluoro-PB-22; 5F-PB-22).............................
quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; 15 g
QUPIC).................................................
------------------------------------------------------------------------
Comments
Pursuant to 21 CFR 1303.11, any interested person may submit
written comments on or objections to these proposed determinations.
Based on comments received in response to this notice, the Deputy
Administrator may hold a public hearing on one or more issues raised.
In the event the Deputy Administrator decides in his sole discretion to
hold such a hearing, the Deputy Administrator will publish a notice of
any such hearing in the Federal Register. After consideration of any
comments and after a hearing, if one is held, the Deputy Administrator
will publish in the Federal Register a final order establishing the
2014 aggregate production quota for PB-22, 5F-PB-22, AB-FUBINACA, and
ADB-PINACA.
Dated: February 28, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014-05024 Filed 3-6-14; 8:45 am]
BILLING CODE 4410-09-P